|
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
|
23 June 2017 |
|
Roche's employee-driven philanthropic campaign sets new record
|
14 June 2017 |
|
Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
|
09 June 2017 |
|
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
|
24 May 2017 |
|
New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis
|
26 April 2017 |
|
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
|
10 April 2017 |
|
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
|
04 April 2017 |
|
FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis
|
29 March 2017 |
|
Roche Annual General Meeting 2017
|
14 March 2017 |
|
Phase III APHINITY study shows Roche's Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy
|
06 March 2017 |
|
Roche reports good results in 2016
|
01 February 2017 |
|
FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer
|
12 January 2017 |
|
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study
|
22 December 2016 |
|
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
|
09 December 2016 |
|
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
|
18 November 2016 |
|
Roche delivers good sales growth in the first nine months of 2016
|
24 October 2016 |
|
FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
|
19 October 2016 |
|
FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
|
05 October 2016 |
|
Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Index for the eighth year running
|
09 September 2016 |
|
Roche delivers continued growth in the first half of 2016
|
25 July 2016 |